FDA Approves Lumipulse Blood Test to Aid Alzheimer’s Diagnosis

Lima, OH, October 16, 2026 —

The U.S. Food and Drug Administration approved Lumipulse in May 2025, according to the information provided. The test is described as the first blood test designed to aid in the diagnosis of Alzheimer’s disease.

The approval introduces a blood-based option alongside traditional diagnostic methods identified in the account: PET scans and spinal taps. Lumipulse is described as less invasive and more accessible than those methods. The summary does not provide details about how the test is administered, which patients it is intended for, or how clinicians are expected to use its results.

The approval is presented as a potential way to support earlier treatment by making diagnosis more accessible. However, the information provided does not establish how often the test leads to earlier diagnosis or treatment, nor does it include clinical performance data. It also does not specify the test’s availability, cost, or whether additional evaluation is needed to confirm a diagnosis.

Those details would help clarify how Lumipulse may fit into Alzheimer’s care. The summary identifies the FDA approval and the test’s intended diagnostic role, but does not name its manufacturer or provide further information about the approval’s conditions. The account characterizes the development as a significant change in diagnostic options while describing its potential effect on patient care rather than reporting measured outcomes.

Story summarized from the original created by Heather Graf on www.hometownstations.com, see more information here.

Media gallery